Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Terns Pharmaceuticals Inc.
TERN | US
44.29
USD1.47
3.43%
TERN | US
About Terns Pharmaceuticals Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
44.29
Open
42.54
High
44.38
Low
41.70
Terns Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops small-molecule single-agent and combination therapy candidates for the treatment of oncology non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-701 an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML) a form of cancer that starts in bone marrow. It also develops TERN-501 a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601 a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases such as obesity. The company was incorporated in 2016 and is headquartered in Foster City California.
View LessTERN | US
Risk
30.7
Sharpe
10.34
Luna's Score
67/100
Recommendation
Buy
Luna says (TERN | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
31.8%1 month
30.7%3 months
89.8%6 months
130.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.90
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-5.80
Ent. to rev.
337.47
PEG
-
Other Fundamentals
EBITDA
-107.91M
MarketCap
3.74B
MarketCap(USD)
3.74B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-38.92
Short ratio
1.41
Short perc.
6.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
5.61
Range1M
8.19
Range3M
18.14
Volumes: Market Activity
Rel. volume
0.86
Price X volume
68.45M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.80 | - | Cheaper |
| Ent. to Revenue | 337.47 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.90 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 89.84 | - | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 3.74B | - | Par |
